Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC) Meeting Abstract
| Authors: | Shah, A. Y.; Motzer, R. J.; Apolo, A. B.; Powles, T.; Escudier, B.; Zhang, J.; Scheffold, C.; Karumanchi, S.; Nguyen, L. T.; Choueiri, T. K. |
| Abstract Title: | Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120602309 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.4561 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4561 -- Source: Wos |
